BIM
SUPN icon

Bogle Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Bogle Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19,100
Closed -$481K – 105
2020
Q4 		$481K Buy
+19,100
New +$411K 0.76% 52
2018
Q3 		– Sell
-229,253
Closed -$13.7M – 329
2018
Q2 		$13.7M Buy
229,253
+47,407
+26% +$2.46M 0.99% 20
2018
Q1 		$8.33M Buy
+181,846
New +$7.59M 0.63% 67
2017
Q3 		– Sell
-242,661
Closed -$10.5M – 345
2017
Q2 		$10.5M Sell
242,661
-117,078
-33% -$4.17M 0.76% 59
2017
Q1 		$11.3M Buy
359,739
+96,555
+37% +$2.59M 0.78% 56
2016
Q4 		$6.64M Buy
263,184
+97,673
+59% +$2.18M 0.46% 78
2016
Q3 		$4.09M Buy
+165,511
New +$3.75M 0.3% 110
2015
Q4 		– Sell
-502,319
Closed -$7.05M – 439
2015
Q3 		$7.05M Hold
502,319
– – 0.5% 79
2015
Q2 		$8.53M Buy
+502,319
New +$7.15M 0.64% 55

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Bogle Investment Management's SUPN Position: Q1 2021 in Review

Bogle Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2021, closing a stake of 19,100 shares — an estimated $481K sold.

Bogle Investment Management first reported a position in SUPN in Q2 2015 and held it in 9 quarters. The position peaked at $13.7M in Q2 2018. 224 funds tracked by Wall St. Rank hold SUPN as of Q1 2021.

  • Bogle Investment Management reported no remaining Supernus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Bogle Investment Management sold 19,100 Supernus Pharmaceuticals shares in Q1 2021, an estimated $481K.
  • Bogle Investment Management first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 9 quarters.
  • Bogle Investment Management's Supernus Pharmaceuticals position peaked at $13.7M in Q2 2018.
  • 224 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2021.

Based on Bogle Investment Management's 13F filing for Q1 2021.